The first drug ever approved for myelofibrosis, ruxolitinib (Jakafi, Incyte/Novartis), is useful only in about 25% of patients with this disorder, according to Ayalew Tefferi, MD, from the division of hematology at the Mayo Clinic Rochester, Minnesota. Even then, it might not be the best option, he added. Dr. Tefferi was speaking to Medscape Medical News about his editorial published in the March 1 issue of the New England Journal of Medicine, which accompanies 2 pivotal clinical trials that formed the basis of the approval of ruxolitinib.

Medscape, by Zosia Chustecka, 02/29/2012

Tags: Ayalew Tefferi, Hematology, Mayo Clinic Rochester, myelofibrosis, New England Journal of Medicine, Research, ruxolitinib